FILED UNDER SOMETHINGISRAELI >> Health & Lifestyle
An Israeli company has developed a new device that can help patients suffering from paralysis of the foot due to central nervous system injuries learn how to walk properly again.
Foot Drop', is a gait disorder that prevents a person from raising their foot while walking, resulting in a dragged foot and instability. It is caused by anything from a stroke, to a brain or spinal cord injury, cerebral palsy, or multiple sclerosis.
The NESS L300 developed by Ra'anana-based NESS (Neuromuscular Electrical Stimulation Systems), is an advanced system designed to improve gait in people suffering from this condition. The wireless, computer controlled device, which received CE mark certification last month, works via electrical stimulation and is located next to the foot and knee of the patient.
"People with foot drop cannot walk freely because once they begin to lift their leg, their foot stays down. They can't walk normally," explained NESS CEO Shmuel Shany.
"There are two ways to accommodate foot drop in order to allow for any type of walking. The first is to fit the patient with a stable splint, which keeps the foot up all the time, but the walk would be very abnormal and awkward. The other way is to revive the patient's natural walk - the way NESS does - which means any time the leg comes up, so does the foot."
The NESS L300 consists of three main components - a sensor, a microprocessor and a control unit. The sensor in the shoe identifies the walking stage of the paralyzed foot. It then transmits a wireless signal to a microprocessor attached underneath the knee. The NESS L300 system releases a suitable and perfectly-timed electronic pulse to the nerves and muscles that activate the paralyzed foot so as to facilitate the user's next step. The electronic stimulus replaces the nerve signal that would otherwise have arrived from the brain.
The device can be installed and operated by the patient, even if he or she also has a disability in their arms, said Shany.
"The control unit is very small, about the size of a cell phone. It allows the patient to control the system wirelessly - turning it on and off and changing the parameters. One of the most important features is that while the system is very sophisticated, for the user it's very simple. Since we're dealing with people who have often recently suffered a stroke, we need to have a simple system that can be easily used. In addition, most people are affected in their upper limbs and their hands, so we needed to design it so it could be used by one hand, if need be," Shany said.
The device was tested over a period of six months on patients undergoing treatment at the Beit Lowenstein Rehabilitation Centre in Ra'anana, and Shany said that the resulting study was currently being submitted for publication in a medical journal.
"I have always believed in the capabilities of the NESS team. They are world-class professionals who have yet again managed to achieve the inconceivable, and have developed a device which will change the lives of millions," said Moshe Tzimerman, chief financial officer of NESS's main investor, Teuza Venture Capital Fund Group.
According to Shany, the main innovation of the NESS L300 is its wireless capacity.
"Most other solutions to foot drop use the technology of electrodes and wires. This creates two problems - you have to wire the person, and you have to rewire him every time - you need to know the exact location to put the electrodes each time. We did away with the electrodes - our orthosis is self-contained," he said.
The NESS L300 is not the only device NESS has developed to activate paralyzed limbs. Incorporated in 1991, NESS 's first successful product was the NESS H200 (formerly The Handmaster) - a revolutionary non-invasive system for paralyzed hands.
NESS's main investor is Teuza - A Fairchild Technology Venture Ltd. (TASE:TUZA) with a 34% stake. Other investors are businessman Alfred Mann, BG Technologies and Applications (the technology transfer company of Ben Gurion University of the Negev), Johnson and Johnson Development Corporation, ABN Amro Capital, Dow Corporate Venture Capital, Life Sciences Partner, and Israel-United States Binational Industrial Research and Development Foundation (BIRD-F).
The company's European office is in the Netherlands, where it coordinates its European activities. The company has also just received FDA approval.
According to Amit Dar, head of R&D at NESS, "The objective difficulties of the structure of the human leg posed a nearly impossible challenge for our researchers and developers, but the result is a small, elegant and efficient instrument that fits any leg and enables a paralyzed person to independently install it each morning."
Reproduced with permission: Bicom